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Introduction {#s002}
============

S[tudies have shown]{.smallcaps} a greater magnitude of glycated hemoglobin (HbA~1c~) change at higher versus lower baseline HbA~1c~ levels following pharmacologic intervention in participants with type 1 (T1D) and type 2 diabetes (T2D).^[@B1]^ Meta-analyses have reported this effect in studies across 8 and 10 categories of noninsulin diabetes therapies, irrespective of medication class or mode of action.^[@B4],[@B5]^ Furthermore, randomized, controlled trials in patients with T1D and T2D have demonstrated this effect as well when adding additional therapy such as dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, or glucagon-like peptide-1 mimetics to their insulin regimen.^[@B1],[@B6]^ This phenomenon may be linked to the impact of chronic glucose toxicity on pancreatic ß-cell function,^[@B12]^ and that medications that address this condition would likely result in more significant HbA~1c~ reductions among individuals with extremely elevated baseline HbA~1c~ (characteristic of glucose toxicity) than in those with lower baseline levels when pancreatic ß-cell function is restored.

However, reducing glucose toxicity does not explain how interventions that modify behavior, such as real-time continuous glucose monitoring (rtCGM), would lower HbA~1c~ from higher levels. rtCGM measures glucose and provides users with glucose numbers, glucose trends, and alerts for impending or actual hypoglycemia and hyperglycemia. It remains uncertain if insulin-treated individuals with the worst glucose control---who may have contributing factors such as poor numeracy skills, poor medication or monitoring adherence, psychosocial issues, eating disorders, or profound fear of hypoglycemia---would have similar improvement in blood glucose control driven by change in behavior with the rtCGM data compared to people who are closer to HbA~1c~ goal.

In a 2011 meta-analysis, Pickup et al. observed that although rtCGM use was associated with a significant reduction in HbA~1c~ in patients with T1D, the largest reductions were seen in individuals with the highest HbA~1c~ values at baseline and in those who used their rtCGM device most frequently.^[@B13]^ The observation from this analysis has not yet been reported in a randomized clinical trial.

The recent DIAMOND study evaluated the effect of older generation rtCGM on glycemic control in multiple daily injection (MDI)-treated T1D and T2D adults with elevated HbA~1c~ levels. Results from analysis of the T1D and T2D study participants across a wide age range (26--79 years) showed that routine use of rtCGM compared with self-monitoring of blood glucose (SMBG) resulted in a greater decrease in HbA~1c~ level during 24 weeks and high rtCGM adherence.^[@B14],[@B15]^ Similar benefits were observed across ages, educational levels, and numeracy skills of participants. A subsequent report from the T1D cohort found CGM to be cost-effective and a sensitivity analysis demonstrated even greater economic benefit with current CGM that eliminates the need for routine fingersticks and extends CGM wear duration.^[@B16]^

In this report, we present findings from a post hoc analysis that investigated the relationship between baseline HbA~1c~ thresholds and the magnitude of HbA~1c~ reductions among the DIAMOND study participants with elevated baseline levels (≥8.0%--10.0%). Additional analysis was conducted on the subgroup of participants with baseline HbA~1c~ ≥9.0%--10.0%, regarding their satisfaction with and adherence to rtCGM.

Methods {#s003}
=======

The DIAMOND trial was composed of two independently powered trials in adult participants using multiple daily insulin injections, one with T1D and the second with T2D. The study was conducted at 27 endocrinology practices across North America. The study is listed on [www.clinicaltrials.gov](www.clinicaltrials.gov), under identifier NCT02282397. Details of the protocol and methods have been published^[@B14],[@B15]^; relevant aspects of the protocol are summarized herein.

Study participants {#s004}
------------------

Major eligibility criteria for this analysis included age ≥25 years, diagnosis of T1D or T2D being treated with MDI of insulin for at least 1 year, central laboratory measured HbA~1c~ ≥7.5%--10.0%, stable diabetes medication regimen and weight over the prior 3 months, self-reported blood glucose meter testing averaging two or more times per day for T2D and three or more for T1D, and estimated glomerular filtration rate ≥45. Major exclusion criteria were use of rtCGM within 3 months of screening and any medical condition(s) that would make it inappropriate or unsafe to target an HbA~1c~ of \<7.0% per investigator discretion.

Study design {#s005}
------------

Details of the study design have previously been published.^[@B14],[@B15]^ Participants in both groups received minimal, basic general diabetes education. Participants using rtCGM received limited device training and CGM management suggestions by a one-page tri-fold handout. This handout contained general guidelines about using rtCGM, and was reviewed at rtCGM initiation and week 4 and 12 visits. Clinicians provided individualized recommendations about each participant\'s goals and how to incorporate rtCGM trend information into their diabetes management. To have the study reflect clinical practice across the United States, specific insulin adjustments were not prescriptive in the protocol for either group, but instead were at the discretion of treating clinicians at the clinical sites. Follow-up clinic visits for both treatment groups occurred at 4, 12, and 24 weeks. There was only one scheduled study-related encounter before the final visit after week 4.

At week 24, satisfaction with rtCGM was assessed by completion of the CGM Satisfaction Survey (44 items on a 1--5 Likert scale, with the computed score representing the mean of the 44 items and subscales of benefits and lack of hassles).^[@B17]^ Adherence to CGM was assessed during the last month of the study. Self-reported insulin dosing frequency was reported at baseline and at week 24.

Statistical methods {#s006}
-------------------

The primary outcome was change in the central laboratory-measured HbA~1c~ from baseline to 24 weeks; a secondary analysis measured HbA~1c~ change at 12 weeks. In this post hoc analysis, change in HbA~1c~ was stratified by baseline HbA~1c~ thresholds and comparisons between rtCGM and control groups. Treatment group comparisons were made with propensity scores,^[@B18]^ adjusted for baseline HbA~1c~ level and clinical site. For all analyses, missing HbA~1c~ values in which the central lab was missing, but local lab was known, were imputed using a regression line based on the site\'s local HbA~1c~ measurements (rtCGM/control: 1/0 at 12 weeks; 1/0 at 24 weeks). *P*-value \<0.05 was considered significant to account for multiple comparisons. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).

Results {#s007}
=======

The DIAMOND studies included 158 T1D and 158 T2D participants treated with MDI; mean baseline values were 8.6% for both T1D study groups and 8.5% for both T2D study groups.^[@B14],[@B15]^ The demographic characteristics of both analysis populations have been reported previously.^[@B14],[@B15]^ This analysis included 131 T1D participants (rtCGM, *n* = 86; control, *n* = 45) and 120 T2D participants (rtCGM, *n* = 63; control, *n* = 57) with baseline HbA~1c~ ≥8.0%--10%, and excluded study participants with lower baseline HbA~1c~ values. Magnitude of HbA~1c~ change in the full cohort (baseline HbA~1c~ ≥7.5%--10%) is reported for comparison purposes.

In all study groups, the change in HbA~1c~ was significantly greater among participants in the rtCGM group compared to SMBG at all predefined HbA~1c~ thresholds at 12 and 24 weeks ([Fig. 1](#f1){ref-type="fig"}). Among the rtCGM users, the change in HbA~1c~ was greatest in the highest HbA~1c~ subgroup (≥9.0%), with similar decreases seen in both the T1D and T2D groups. At 24 weeks, the impact of baseline HbA~1c~ on reductions was minimal in the T1D and T2D control groups.

![Comparisons of HbA~1c~ outcomes at 24 weeks according to baseline HbA~1c~ levels by patient subgroup. HbA~1c~, glycated hemoglobin; rtCGM, real-time continuous glucose monitoring; T1D, type 1 diabetes; T2D, type 2 diabetes.](fig-1){#f1}

Among participants with HbA~1c~ ≥9.0%, CGM satisfaction based on the CGM Satisfaction Survey demonstrated no difference versus those with a lower HbA~1c~ on perception of the benefits or lack of hassles with CGM. In addition, adherence remained high in those with HbA~1c~ ≥9.0% with 93% of the combined T1D and T2D CGM cohorts using CGM ≥6 days per week the last month of the study.

Discussion {#s008}
==========

The DIAMOND study program demonstrated significant improvements in HbA~1c~ at 12 and 24 weeks in T1D and T2D participants who used rtCGM compared with those using a blood glucose meter alone for glucose monitoring.^[@B14],[@B15]^ It is clear that use of rtCGM is an effective tool for patients with diabetes to improve control, but the question remained whether rtCGM use would benefit participants with the worst control in a low-touch clinical trial.

In this analysis, we observed a consistently greater reduction in HbA~1c~ at all baseline HbA~1c~ subgroups with rtCGM compared to SMBG. The greatest reductions were observed at the highest HbA~1c~ threshold ≥9%, corroborating the observations by Pickup et al.^[@B13]^ This pattern of greater reductions at higher baseline HbA~1c~ thresholds is not seen in the SMBG group and therefore cannot be attributed to enrollment in a clinical trial or regression to a mean, but rather the initiation of an effective behavioral intervention tool, rtCGM.

Unlike pharmaceutical studies, in which the investigators assess a given medication\'s known mechanism of action and glucose-lowering ability, medical device studies are more complicated. Understanding how behavior-based interventions function is more complex because the mode of action involves both device performance and behavioral response from study participants and/or their treating clinicians.

For example, in a survey of adults with T1D, Pettus et al.^[@B19]^ characterized diabetes management behaviors based on rtCGM that would translate into HbA~1c~ reduction. Survey respondents reported that rtCGM high-glucose alerts enabled them to respond to episodes of nocturnal hyperglycemia, which typically goes unrecognized and presents a potential large glycemic burden. The majority of survey respondents also stated that they took more insulin boluses or injections per day since starting on rtCGM. This was also observed in the SWITCH trial.^[@B20],[@B21]^ In addition, most survey respondents reported adjusting their insulin timing relative to a meal and their meal insulin dose, based on the rtCGM trend arrows. Finally, many users lowered their glycemic targets since starting on CGM, which was likely related to less fear of hypoglycemia. Based on the results, it appears that the patients with poorly controlled diabetes made some of these diabetes management modifications based on their CGM data to derive significant benefit.

In this study, T1D and T2D participants with HbA~1c~ ≥9% randomized to rtCGM had a notable reduction in mean HbA~1c~ −1.4 ± 0.7 from baseline to study end. Compared to control group participants with HbA~1c~ \>9.0%, this large reduction is similar to findings observed in trials that intensified therapy with additional medications in T1D and insulin-treated T2D with poorly controlled diabetes.^[@B1],[@B6]^ Thus, we demonstrated that rtCGM has similar glycemic benefits compared to additional pharmacotherapy by empowering patients and clinicians, while eliminating the downsides of adding further medications.

Importantly, rtCGM use was sustained throughout this study,^[@B14],[@B15]^ and participants noted high satisfaction with rtCGM in responses to the rtCGM Satisfaction Survey,^[@B17]^ with no difference in responses when examined by baseline HbA~1c~ levels. These findings support the hypothesis that high treatment satisfaction results in high adherence, and that high adherence results in glycemic benefit, even within the study population with the worst baseline control.

These findings also have implications for payers. Data from the NHANES survey demonstrated that 36.9% of insulin plus oral agent users and 49.1% of adult insulin-only users in the United States had an HbA~1c~ ≥8.0%.^[@B22]^ The landmark Diabetes Control and Complication Trial showed a curvilinear relationship between HbA~1c~ and risk of development and progression of complications---there was an exponential increase in risk observed as HbA~1c~ levels incrementally increased to higher levels.^[@B23]^ Patients with incrementally higher HbA~1c~ levels \>7.5% have been shown to progressively increase health system costs,^[@B24]^ and have the greatest economic benefit from improving their glycemic control.^[@B25]^ A 1.0% reduction in HbA~1c~ from 10.0% to 9.0% is associated with \$805 saving \>3 years in adults with diabetes, but without heart disease and hypertension.^[@B24]^ The cost saving climbs to \$1,130 in those with hypertension, \$2,078 with heart disease, and \$2,675 with both hypertension and heart disease.^[@B24]^ Among the 49 participants in the rtCGM group with a measured HbA~1c~ ≥9.0%, 20 had hypertension and 4 had diagnosed coronary disease.

Conclusions {#s009}
===========

The objective of these analyses was to determine whether and to what degree high baseline HbA~1c~ values are associated with subsequent changes in glycemic status among MDI-treated T1D and T2D participants. As reported in this study, a positive relationship between high baseline HbA~1c~ values and improvements in glycemic status was observed among all study participants regardless of monitoring method. However, the magnitudes of improvements appeared greater among participants using rtCGM and were similar to those seen in pharmaceutical studies.^[@B1],[@B6]^ Importantly, the improvements seen in patients with high baseline HbA~1c~ levels were achieved without the need for additional medications and associated costs. Thus, the costs of rtCGM in patients with high HbA~1c~ may be offset by avoiding treatment intensification with other medications and costs associated with medication side effects, and the longer-term savings achieved by lowering HbA~1c~ levels in poorly controlled diabetes populations.
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